Mehdi Chelbi

Biotech entrepreneur #Oncology #Immunology- BiPER Therapeutics CEO & Co-Founder First In Class therapeutics to treat GI Cancers - G.CLIPS Biotech Board Member

[Mehdi Chelbi @Mehdical]

@BowTiedBiotech Indeed this is the solution and it exist for real ! Check G.CLIPS enabling technology https://t.co/piQUPT6IbC we are able to produce stabilized membrane proteins in the desired conformation and to perform the pharmacological profiling of NCEs mAbs and CARs 😉

[Mehdi Chelbi @Mehdical]

BiPER Therapeutics is committed to the fight against cancer / BiPER Therapeutics est engage dans la luttte contre le cancer Let s fight together ! #WorldCancerDay #CloseTheCareGap

[Myriam Chalabi @MyriamChalabi]

What a great start of 2024! Excited, happy and proud to share our latest work published today #openaccess @NatureMedicine on the PANDA trial: neoadjuvant atezo+chemo in pts with gastric/GEJ cancers followed by surgery. Some of the key findings below. 1/10 https://t.co/ApfPdsYu2f

[Filippo Pietrantonio @FilippoPietran4]

GI cancers are the main cause of cancer-related deaths worldwide including 1/3 of deaths related to cancers. Yet research is underfunded and hospital staff is underrepresented.

[Max Mamonkin @MaxMamonkin]

GRP78 is a promising new pan-cancer target for CAR-T therapy (but with a twist). Great preclinical study by @Jorge88382322 @GiedreKrenciute @PaulinaV_MD and the St Jude team https://t.co/OerzVlEB05

[Mehdi Chelbi @Mehdical]

@MaxMamonkin @Jorge88382322 @GiedreKrenciute @PaulinaV_MD Great work confirming GRP78 as a relevant target to treat cancers

[Mehdi Chelbi @Mehdical]

@tariqkrim @Xavier75 @Xavier75 il y a des choses a faire sur les 3 volets. Pret a y contribuer et partager mon retour d experience.

[Luca Falzone @lucafk92]

Our SnapShot on Cancer Chemotherapy has just been published in
@CellCellPress https://t.co/3DGsuXiKcb
#Cancer #Chemotherapy #CancerResearch

[Arndt Vogel @ArndtVogel]

🔥Just out: The ESMO #GastricCancer Living Guideline
👉get the latest news & updates for daily decision making
@myESMO @OncoAlert

[Laure Chotel @LaureChotel]

'BRAFV600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist'
https://t.co/QuDXCBGklU
My husband and I share our views on #BRAFV600E #CRC as a #patient and a #caregiver with the expert Christelle de la Fouchardière

[Xavier Leroy, PhD, EMBA @DrXavierLeroy]

Revealing the signaling of complement receptors C3aR and C5aR1 by anaphylatoxins | Nature Chemical Biology https://t.co/RuglO6KWed

[Mehdi Chelbi @Mehdical]

@AssurancesBPCE Merci. J attends donc que cela avance concretement et rapidement. Bien a vous

[Mehdi Chelbi @Mehdical]

@AssurancesBPCE est ce que vous comptez repondre un jour ?? 6 mois depuis mon degat des eaux et AUCUNE reponse ni par mail ni par telephone 😡😡😡 !!!!

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC position article and guidelines: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer https://t.co/sJKxuVlo6L @VanMorrisMD @mdmanishshah @DrRonanKelly

[Gastric Cancer Foundation @GastricCancerFD]

At @ASCO, @BeiGeneGlobal presented positive results from their phase 3 study of tislelizumab plus chemotherapy as a first-line treatment of advanced gastric cancer that demonstrated meaningful improvement in overall survival. https://t.co/wrCy2FCaqn

[Mehdi Chelbi @Mehdical]

@jsoriamd Thanks Dr @jsoriamd we are targeting an explored one @ BiPER Therapeutics and hope to make our asset enter into the clinic very soon 😉

[Ibrahim Halil SAHIN, MD @IbrahimSahinMD1]

✳️A nice article showing tumor mutation burden alone relatively irrelevant for IO response among MSS GI cancers particularly for MSS CRC❗️

Why?👇

@OncoAlert @TheColonClub @TheColonClub @manjuggm @UPMCHillmanCC

https://t.co/m2LnHS0I6y

[Yamina Berchiche @yaminaberchiche]

Amazing day! #gpcr #drgpcr

[Mehdi Chelbi @Mehdical]

BiPER Therapeutics fait partie de le selection @Challenges des 100 start ups ou #investir. Notre candidat medicament a une approche unique pour traiter les patients atteints de #Cancers gastrointestinaux https://t.co/mZAyyCkTPy

[nature @Nature]

Nature research paper: Autoregulation of GPCR signalling through the third intracellular loop https://t.co/xnkG3nL7yY